Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024 [Yahoo! Finance]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Yahoo! Finance
global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present the latest data from two clinical studies of selinexor in two Posters at the 2024 American Society of Hematology Annual Meeting (ASH 2024), taking place on December 7-10, 2024 , in San Diego, CA the United States Details on the Posters: Title: Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase III Bench Study Publication Number: Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster III Date: Monday, December 9, 2024 Time: 6:00 PM - 8:00 PM (Eastern time) 00 AM - 9:00 AM December 10, 2024 Beijing time) First Author: Dr. Jin Lu (Peking University People's Hospital) Corresponding Author: Dr. Jian Hou (Ren Ji Hospital, Shanghai
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region [Yahoo! Finance]Yahoo! Finance
- Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025PR Newswire
- Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $3.00 price target on the stock.MarketBeat
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
KPTI
Earnings
- 11/5/24 - Beat
KPTI
Sec Filings
- 2/12/25 - Form SCHEDULE
- 2/5/25 - Form 4
- 2/3/25 - Form 4
- KPTI's page on the SEC website